logo
More grievances against prosthetic eye maker Jack McDonald's work

More grievances against prosthetic eye maker Jack McDonald's work

Ron Clark lost an eye after developing a severe infection.
"The eye sort of melted, and they had to do emergency surgery to remove it," he said.
As a consultant who spends much of his time doing business face-to-face, Mr Clark was eager to have an artificial eye made.
But he was very unhappy with the eye made for him by ocularist Jack McDonald, which he said "bulged out of the socket".
He said the situation became "intolerable" after the eye fell out while he was at dinner.
"It was quite undesirable and confronting — a bit embarrassing frankly," he said.
Mr Clark decided to speak out after other clients of Mr McDonald shared their experiences with the ABC.
"I don't want anybody else to suffer through like I have," he said.
Mr McDonald is described on his website as a trained ocularist and maxillofacial (face and jaw) prosthetist providing "ultra-realistic and world-class prostheses".
His website states his services include prosthetic eyes, ears, fingers and noses.
Previously, his website stated Mr McDonald was operating out of offices in Sydney, Melbourne, Dandenong, Hobart, Adelaide, Brisbane, Perth, Geelong and Auckland.
Now, his website no longer lists the locations he works from, but there are contact numbers for Sydney and Melbourne offices.
Fifteen people contacted the ABC with similar stories of disappointment and dissatisfaction with Mr McDonald's work after the initial story about him was published.
"It's something that brings out a lot of emotion in me because it's a very confronting experience," Mr Clark said.
Do you know more? Contact Fiona Blackwood at blackwood.fiona@abc.net.au.
Mr Clark said his experience with Mr McDonald was characterised by "multiple visits, multiple cancellations, multiple attempts at creating the eye, followed by a failure to succeed".
Mr Clark lost faith in the process and has since had an eye made with a different ocularist, which he is very satisfied with.
The president of the Ocularists Association of Australia, Peter Knowles, who has more than 35 years of experience, took a look at the eye Mr McDonald made for Mr Clark.
He described it as unsightly and "bulging, its gaze is upward, its colour doesn't match".
"It's loading the lower eyelid in a manner that could cause damage and therefore [could] need surgical construction," Mr Knowles said.
Mr Knowles said he also received phone calls from unhappy clients of Mr McDonald after the ABC story was published.
Mr Knowles is concerned Mr McDonald is continuing to see patients.
Liana* lost her eye to melanoma when she was just 29.
She initially saw Jack McDonald for an unrelated matter last year, and he promised he could make her a better artificial eye than the one she already had.
With high hopes, Liana paid $2,800 up front for the eye at her first appointment in August last year.
She said she attended 11 appointments, but Mr McDonald struggled to get the eye right.
"The prosthetic he created looked unnatural and was the wrong size; it protruded so far that it was unsettling to look at," she said.
Liana said she also received frequent text messages from Mr McDonald's office cancelling or rescheduling appointments.
"On the last occasion, when they blamed flight delays from Hobart, I checked all carriers and found no cancellations or delays that day," she said.
She twice asked Mr McDonald for a refund, but was refused.
In the end, she provided evidence to her bank demonstrating that she had not received an acceptable eye and the bank agreed to reverse the $2,800 credit card payment to Mr McDonald.
Liana's experience has come at a personal cost.
"My experience with Jack was traumatic, losing my eye to cancer in 2019 was one of the hardest years of my life, and Jack reopened many of those emotional wounds while making me feel even more insecure," she said.
She is calling for regulation of the industry.
"There needs to be someone there to say: 'Your work is not up to standard, you can't be operating,'" she said.
There are no government regulatory hurdles to clear before being able to act as an ocularist in Australia and no requirement to be a member of an Ocularist Association.
Mr McDonald is not a member of the Ocularist Association of Australia, nor is he required to be.
He has not responded to the ABC's request for comment.
Wayne Dryden described his year-long wait for Jack McDonald to make him a suitable eye as "one of the worst experiences" of his life.
He said after 21 appointments, he has given up hope Mr McDonald will ever make him a wearable artificial eye.
Those so far have been the wrong colour, ill-fitting and painful, he said.
"Absolutely terrible and very disheartening," Mr Dryden said.
Mr Dryden took out a bank loan to pay $2,800 for the eye.
With travel costs associated with his many appointments, he said his efforts for a suitable prosthetic have "roughly cost me $6,000 within the 12 months".
He said he pursued a refund, but Mr McDonald refused.
Mr Dryden is having to make do with a scratched artificial eye, which he has had for more than 30 years — as he can't afford to see another ocularist.
He said he wants to take legal action against Mr McDonald, but can't afford that either.
"He needs to be accountable for what he's done to people, not only myself, other people."
Ocularist Peter Knowles has encouraged unsatisfied clients of Jack McDonald to go to their state's Health Complaints Commission.
But he is concerned that many clients with grievances, like Mr Dryden, are out of pocket.
He said while some clients can't afford legal fees, clients could consider a class action.
Mr Knowles said people who have lost an eye through trauma, birth deformity or disease are vulnerable, and there "should be a mechanism whereby a person can be made accountable".
'There is no such thing as pleasant eye loss … and so to give them back an eye is to give them back their connection with people," he said.
The unregulated nature of the industry means avenues for help or refunds are unclear, according to the Health Consumers Commission.
"The health complaints space is a very busy and sometimes very messy area to navigate as a community member," chief executive Dr Elizabeth Deveny said.
The Health Consumers Commission is calling on the federal government to bring the sector together with clients and clinicians to talk about how best to improve the situation.
"These devices affect people's lives in their function, their dignity, their ability to do things.
"It's terrible to hear that people have had a very poor experience."
*Name has been changed for privacy.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ASX Health July Winners: Sector finally catches a bid to rebound 9pc for month
ASX Health July Winners: Sector finally catches a bid to rebound 9pc for month

News.com.au

timea minute ago

  • News.com.au

ASX Health July Winners: Sector finally catches a bid to rebound 9pc for month

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of FebriDX in US subject to CLIA waiver Clever Culture Systems rose 81.3% in July on news global pharmaceutical giant Novo Nordisk purchased one of its flagship APAS Independence instruments for evaluation The healthcare sector rose 9.05% in July to be the best of the 11 ASX sectors. A turn up for the books to be sure. While remaining the worst performing sector YTD – up just 1.81% – the S&P ASX Health Care index was in recovery mode in July. The sector was buoyed by a roughly 13% rise in its biggest name blood products giant CSL (ASX:CSL), which drives much of the index. Morgans' healthcare analyst Iain Wilkie said there appeared to be a strong sector rotation on the ASX in July. "During July there certainly was a rotation out of usual strong sectors like financials and more into healthcare and the miners," he told Stockhead. "Healthcare has been beaten down for quite a long while now and is starting to look attractive. "I don't think there was anything specific in terms of a catalyst to drive the rotation." Looking ahead, Wilkie noted the sector may face continued pressure with US President Donald Trump again threatening tariffs " at a very, very, high rate, like 200%" on imported pharmaceuticals. "Trump has again thrown his weight around but until it actually hits we'll see," Wilkie said. He said US tariffs shouldn't affect companies like CSL, which is one of the world's largest manufacturers of plasma products. "Although the US collects over 60% of the world's plasma, it lacks sufficient domestic capacity to process it into finished therapies," he said. "As a result, imported plasma products are critical to meeting national demand. "Introducing tariffs on these products would likely be counterproductive as they wouldn't foster viable domestic alternatives and could drive up costs, potentially limiting patient access and causing harm." How ASX biotechs performed in July CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP PAB Patrys Limited $ 0.002 181.8% 6.9 LDX Lumos Diagnostics $ 0.073 170.4% 55.4 NSB Neuroscientific $ 0.235 170.1% 79.8 NXS Next Science Limited $ 0.140 109.0% 41.7 NOX Noxopharm Limited $ 0.110 103.7% 30.7 CMB Cambium Bio Limited $ 0.425 102.4% 8.2 DVL Dorsavi Ltd $ 0.028 86.7% 27.3 ICR Intelicare Holdings $ 0.013 85.7% 6.3 CC5 Clever Culture $ 0.029 81.3% 56.9 EMD Emyria Limited $ 0.049 75.0% 28.1 CU6 Clarity Pharma $ 4.370 74.8% 1,471.5 HMD Heramed Limited $ 0.012 71.4% 10.5 MX1 Micro-X Limited $ 0.083 69.4% 54.0 TTX Tetratherix Limited $ 5.020 66.2% 131.7 CAN Cann Group Ltd $ 0.016 60.0% 9.8 NYR Nyrada Inc. $ 0.370 54.2% 77.8 VBS Vectus Biosystems $ 0.06 50.0% 3.2 CSX Cleanspace Holdings $ 0.760 46.2% 59.5 MSB Mesoblast Limited $ 2.380 43.8% 3,046.3 AVE Avecho Biotech Ltd $ 0.005 42.9% 15.9 HIQ Hitiq Limited $ 0.020 42.9% 9.9 AYA Artryalimited $ 1.025 42.4% 116.7 ANR Anatara Ls Ltd $ 0.007 40.0% 1.5 ATH Alterity Therap Ltd $ 0.014 40.0% 128.9 CBL Control Bionics $ 0.040 37.9% 12.1 EYE Nova EYE Medical Ltd $ 0.150 36.4% 41.2 IBX Imagion Biosys Ltd $ 0.015 36.4% 3.0 IPD Impedimed Limited $ 0.047 34.3% 93.4 RCE Recce Pharmaceutical $ 0.388 33.6% 108.4 NTI Neurotech Intl $ 0.020 33.3% 21.0 VFX Visionflex Group Ltd $ 0.00 33.3% 6.7 AT1 Atomo Diagnostics $ 0.018 28.6% 14.2 AHC Austco Healthcare $ 0.370 27.6% 137.0 TRP Tissue Repair $ 0.240 26.3% 14.5 SOM SomnoMed Limited $ 0.815 25.4% 171.8 1AD Adalta Limited $ 0.003 25.0% 2.8 ADR Adherium Ltd $ 0.005 25.0% 9.0 BIT Biotron Limited $ 0.003 25.0% 3.3 CUV Clinuvel Pharmaceut. $ 12.970 25.0% 617.5 FRE Firebrickpharma $ 0.077 24.2% 17.5 CMP Compumedics Limited $ 0.315 23.5% 66.3 NEU Neuren Pharmaceut. $ 17.290 22.5% 2,150.6 ILA Island Pharma $ 0.170 21.4% 40.8 ATX Amplia Therapeutics $ 0.240 20.0% 111.9 DOC Doctor Care Anywhere $ 0.125 19.0% 47.7 EBR EBR Systems $ 1.410 18.0% 514.6 LTP Ltr Pharma Limited $ 0.340 17.2% 60.6 PAR Paradigm Bio. $ 0.355 16.4% 136.1 LGP Little Green Pharma $ 0.115 16.2% 35.1 M7T Mach7 Tech Limited $ 0.380 15.2% 89.3 ALC Alcidion Group Ltd $ 0.115 15.0% 154.4 NC6 Nanollose Limited $ 0.077 14.9% 24.1 CYC Cyclopharm Limited $ 1.040 14.3% 113.4 SPL Starpharma Holdings $ 0.100 13.6% 43.9 MVF Monash IVF Group Ltd $ 0.800 13.5% 309.8 SNT Syntara Limited $ 0.060 13.2% 97.6 CSL CSL Limited $ 270.900 13.1% 128,514.7 PME Pro Medicus Limited $ 321.890 12.9% 33,058.3 CVB Curvebeam Ai Limited $ 0.080 12.7% 33.2 IMM Immutep Ltd $ 0.270 12.5% 385.3 MVP Medical Developments $ 0.610 11.9% 64.8 TRJ Trajan Group Holding $ 0.800 11.9% 121.9 GLH Global Health Ltd $ 0.076 11.8% 4.5 VIT Vitura Health Ltd $ 0.07 11.3% 47.0 PIQ Proteomics Int Lab $ 0.360 10.8% 57.3 IRX Inhalerx Limited $ 0.042 10.5% 9.0 IDT IDT Australia Ltd $ 0.098 10.1% 40.7 NUZ Neurizon Therapeutic $ 0.170 9.7% 81.2 PGC Paragon Care Limited $ 0.400 9.6% 653.8 RHY Rhythm Biosciences $ 0.059 9.3% 17.4 1AI Algorae Pharma $ 0.006 9.1% 10.1 CTQ Careteq Limited $ 0.012 9.1% 2.8 AHX Apiam Animal Health $ 0.565 8.7% 103.0 ARX Aroa Biosurgery $ 0.630 8.6% 224.3 OCC Orthocell Limited $ 1.275 8.5% 309.7 MAP Microbalifesciences $ 0.092 8.2% 47.4 PSQ Pacific Smiles Grp $ 1.670 8.1% 269.9 PNV Polynovo Limited $ 1.290 7.9% 858.4 RMD ResMed Inc. $ 42.450 7.9% 61,930.3 PTX Prescient Ltd $ 0.047 6.8% 38.7 REG Regis Healthcare Ltd $ 8.370 6.8% 2,545.6 TYP Tryptamine Ltd $ 0.03 6.7% 44.6 SDI SDI Limited $ 0.883 6.3% 104.6 COH Cochlear Limited $ 318.520 6.0% 20,541.2 RHC Ramsay Health Care $ 38.770 5.7% 8,808.5 IDX Integral Diagnostics $ 2.670 5.1% 1,001.8 IMC Immuron Limited $ 0.064 4.9% 16.9 OCA Oceania Healthc Ltd $ 0.660 4.8% 461.5 EBO Ebos Group Ltd $ 37.250 4.7% 7,552.6 RAD Radiopharm $ 0.023 4.5% 54.4 ACW Actinogen Medical $ 0.024 4.3% 76.3 IIQ Inoviq Ltd $ 0.385 4.1% 43.5 AGH Althea Group $ 0.026 4.0% 21.4 IME Imexhs Limited $ 0.300 3.4% 15.8 CYP Cynata Therapeutics $ 0.155 3.3% 37.3 SHL Sonic Healthcare $ 27.610 3.1% 13,532.2 FPH Fisher & Paykel H. $ 34.090 1.4% 19,481.0 CTE Cryosite Limited $ 0.750 0.7% 36.6 VLS Vita Life Sciences.. $ 2.26 0.4% 124.4 ACR Acrux Limited $ 0.016 0.0% 7.0 BP8 Bph Global Ltd $ 0.002 0.0% 2.1 EMV Emvision Medical $ 1.740 0.0% 150.1 EOF Ecofibre Limited $ 0.020 0.0% 7.6 EPN Epsilon Healthcare $ 0.024 0.0% 7.2 NAN Nanosonics Limited $ 4.050 0.0% 1,196.3 OSX Osteopore Limited $ 0.011 0.0% 2.6 TD1 Tali Digital Limited $ 0.001 0.0% 4.2 TRI Trivarx Ltd $ 0.008 0.0% 5.0 TRU Truscreen $ 0.016 0.0% 12.3 ACL Au Clinical Labs $ 2.760 -0.7% 536.1 CGS Cogstate Ltd $ 1.730 -0.9% 292.9 MYX Mayne Pharma Ltd $ 4.950 -1.0% 405.4 ANN Ansell Limited $ 29.950 -1.1% 4,410.5 AFP Aft Pharmaceuticals $ 2.400 -1.2% 259.6 RGT Argent Biopharma Ltd $ 0.080 -1.2% 4.7 RAC Race Oncology Ltd $ 1.160 -1.3% 198.9 SNZ Summerset Grp Hldgs $ 10.300 -1.3% 2,513.8 HLS Healius $ 0.770 -1.9% 548.2 ALA Arovella Therapeutic $ 0.098 -2.0% 117.7 BMT Beamtree Holdings $ 0.245 -2.0% 72.6 ONE Oneview Healthcare $ 0.245 -2.0% 185.7 4DX 4Dmedical Limited $ 0.235 -2.1% 136.2 COV Cleo Diagnostics $ 0.380 -2.6% 48.8 RHT Resonance Health $ 0.038 -2.6% 17.5 AVH Avita Medical $ 1.670 -2.6% 217.6 SIG Sigma Health Ltd $ 2.890 -3.3% 32,726.4 PYC PYC Therapeutics $ 1.240 -4.2% 729.1 IXC Invex Ther $ 0.085 -4.5% 6.9 OIL Optiscan Imaging $ 0.105 -4.5% 87.7 ZLD Zelira Therapeutics $ 0.41 -6.8% 4.9 MDR Medadvisor Limited $ 0.075 -7.4% 43.8 BDX Bcaldiagnostics $ 0.058 -7.9% 20.5 GSS Genetic Signatures $ 0.330 -9.6% 76.1 CDX Cardiex Limited $ 0.036 -10.0% 18.7 PER Percheron $ 0.009 -10.0% 10.9 AGN Argenica $ 0.680 -10.5% 86.1 OSL Oncosil Medical $ 1.070 -10.8% 20.2 ECS ECS Botanics Holding $ 0.008 -11.1% 11.0 PEB Pacific Edge $ 0.085 -11.5% 75.9 IVX Invion Ltd $ 0.096 -12.7% 8.2 EZZ EZZ Life Science $ 2.030 -13.2% 99.1 TLX Telix Pharmaceutical $ 21.050 -13.8% 6,991.3 AVR Anteris Technologies $ 5.130 -16.4% 179.8 DXB Dimerix Ltd $ 0.470 -18.3% 285.1 SHG Singular Health $ 0.300 -18.9% 93.5 IMR Imricor Med Sys $ 1.225 -19.4% 324.2 MEM Memphasys Ltd $ 0.004 -20.0% 7.9 PCK Painchek Ltd $ 0.035 -22.2% 66.3 CHM Chimeric Therapeutic $ 0.003 -25.0% 11.4 VHL Vitasora Health Ltd $ 0.03 -28.2% 46.4 UCM Uscom Limited $ 0.01 -31.3% 2.9 UBI Universal Biosensors $ 0.02 -31.4% 7.2 IMU Imugene Limited $ 0.270 -38.9% 77.2 BOT Botanix Pharma Ltd $ 0.150 -53.1% 289.3 Patrys (ASX:PAB) rose ~182% in July after announcing a solid June quarter including a board restructure, $300,000 capital raise and actively pursuing partnering and licensing opportunities for both of its oncological cell therapy deoxymab assets. In July Patrys also announced a fully underwritten, pro-rata non-renounceable entitlement offer of three fully paid ordinary shares for every four shares held at an issue price of $0.001 per Share, together with on free-attaching new share for every four shares applied for and issued, to raise up to ~$1.78m. Lumos Diagnostics (ASX:LDX) rose more than 170% in July after l anding a landmark six-year distributor deal worth hundreds of millions of dollars to sell its rapid point-of-care diagnostic FebriDx in the US market. The FebriDx product is a simple test able to differentiate between bacterial and non-bacterial acute respiratory infections. The lucrative US licensing deal with Hong-Kong based PHASE Scientific could see Lumos net up to to US$317m (~A$487m), and has been described as one of the largest distribution deals of its type to be done by an ASX-listed point-of-care diagnostics company. Adelaide-based Clever Culture Systems (ASX:CC5), rose 81.3% in July after announcing global pharmaceutical giant Novo Nordisk had purchased one of its flagship APAS Independence instruments for evaluation. The machine will be delivered to Novo's central team in Denmark, where it will undergo a full-scale evaluation to assess its suitability for deployment across Novo's global manufacturing network. The APAS Independence uses AI technology to automate one of the most time-consuming parts of microbiology, analysing agar plates for contamination. Radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) was up 74.8% in July after completing a large $203m institutional placement at a 15% premium to the company's 15-day average price, to fund their clinical program. Executive chairman Dr Alan Taylor told Stockhead the 'fast, well executed and sizeable' placement was to a small group of local institutional investors "close to the company". 'I have never done a deal that fast,' Taylor said. 'A week ago, I would have said we were not doing a capital raising, but there was a lot of interest from a very concentrated group .' At Stockhead, we tell it like it is. While Lumos Diagnostics and Clever Culture Systems are Stockhead advertisers, the companies did not sponsor this article. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead.

'Frustrating and disappointing': Canberra residents with Parkinson's disease still campaigning for a specialist nurse
'Frustrating and disappointing': Canberra residents with Parkinson's disease still campaigning for a specialist nurse

ABC News

time31 minutes ago

  • ABC News

'Frustrating and disappointing': Canberra residents with Parkinson's disease still campaigning for a specialist nurse

Jenny Miragaya has good and bad days. "When I'm off, I can't walk. I can't stand," she said. The proud grandmother, retired midwife and keen cook was 58 when she was diagnosed with Parkinson's disease in 2016. She booked in to see her GP and then a neurologist after noticing her walking had slowed, her voice had quietened and her handwriting had deteriorated. Despite watching the same disease take its toll on her father, the diagnosis came as a shock. "It was awful, I still get teary when I think about it — I just couldn't believe it," Ms Miragaya said. Parkinson's disease is a progressive, degenerative, neurological condition that affects a person's nervous system and their ability to move. It doesn't have a cure, but medication can ease the symptoms, which can include a tremor, stiffness, lack of balance and slurred speech. For Ms Miragaya that was exactly the case, and she revels in running a monthly support group for women in Canberra with Parkinson's disease and singing weekly with the Bushlarks — a choir for people with the condition. But over time her symptoms have become more severe and the efficacy of her medication has reduced. Ms Miragaya is among those in the Parkinson's community who have long been campaigning for the ACT government to employ a specialist Parkinson's nurse who can visit patients at home. Evidence shows specialist nurses who visit patients at home can significantly improve their quality of life, particularly by providing personalised care plans, medication adjustments and safety assessments. They can also help a person to maintain their independence and delay their admission into full-time out-of-home care. "At the moment I'm reasonably okay, but I won't be down the track," Ms Miragaya said. "I will need additional support and assistance if I want to stay in my own home as independently as I can. "And coming from a nursing background, I know how wonderful nurses can be and what they bring to a care team." The community push for a nurse has been going on for a decade, with the first glimmer of hope given ahead of last October's ACT election. It was then that Health Minister Rachel Stephen-Smith made an election commitment to expand the movement disorder centre within the Brindabella Day Service, including providing a specialist Parkinson's nurse who would work in the community. For Marcia Kimball, who is the chair of Parkinson's ACT, it felt like the hard advocacy work was finally paying off. But now, six months on from the election, she is frustrated the more than 3,000 Canberrans living with the disease are still waiting. "It's very frustrating and disappointing for our community that we're still waiting." Ms Kimball said the ACT was now the only jurisdiction in Australia where people with Parkinson's can't access a specialist nurse at home through the public health system. "They have five nurses in South Australia and South Australia is probably three times our population," she said. "All we're asking for is one, which we don't believe is even enough — it's not a lot of money in the scheme of things." Ms Kimball's husband John was diagnosed with Parkinson's disease in 2008 after showing signs of rigidity, a slight tremor, apathy, and an overall slowing down. He has been in full-time residential aged care since 2022. Ms Kimball can't help but wonder how much longer her husband could have remained in the family home had he had access to home visits from a specialist nurse. "With Parkinson's, there's a lack of mobility so it can be really hard on carers and the people living with the disease to go out to clinics. "So, having someone come to you really is invaluable." Ms Stephen-Smith said she was still committed to delivering on her election promise. But when pressed for a timeline, the minister failed to provide one. "Canberra Health Services is working to set up that model to ensure that we get it right and that means working with the community as well and recruiting the advance practice nurse to undertake that work," she said. Ms Miragaya said she can't help but feel "discriminated against" by the lack of action. "These are my people now — I'm a Parky — so to keep me well at home, I may need some additional supports and that may mean I need a nurse to come and assess my home, my safety, my ability to cook or clean or dress or shower," she said. "Whatever I need, it should be readily available for me to access, but not if you've got Parkinson's."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store